Foundation Medicine (NASDAQ:FMI)

CAPS Rating: 4 out of 5


How do you think FMI will perform against the market?

Add Stock to CAPS Watchlist

All Players

44 Outperform
3 Underperform

All-Star Players

11 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top FMI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFInnovator (80.42)
Submitted September 03, 2014

Foundation Medicine runs high-speed genomic tests to profile individual patients, identify genetic abnormalities, and then recommend the best course of action for their treatment. I expect them to benefit from continued adoption of personalized… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

FMI VS S&P 500 (SPY)

Fools bullish on FMI are also bullish on:

Fools bearish on FMI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about FMI.


Member Avatar meridius91 (69.70) Submitted: 10/23/2017 11:30:39 AM : Outperform Start Price: $41.05 FMI Score: +232.41

A leader in the push to personalized genetic medicine at a much earlier stage due to the market niche. Foundation already has a strong industry partner in Roche and if they don't explode on their own they may be acquired. It's riskier, but could be a multi-bagger.


Member Avatar TMFEBCapital (64.81) Submitted: 10/10/2017 3:52:29 PM : Outperform Start Price: $44.05 FMI Score: +208.66

This company's on the cutting edge of genetic screening for cancer mutations and a potential FDA approval for its Foundation One platform by year's end -- and the corresponding issuance of a distinct Medicare code at the same time -- could significantly accelerate the adoption of screening. Personalized medicine is where cancer treatment is heading, and currently, only 150k of an addressable 1 mn person market in advanced cancer is being screened. Over time, expansion of this market could make the addressable market in the U.S. 2 million. Given Roche already own 50% plus of this one, there's plenty of financial backing to make this a reality.


Member Avatar adamicius (< 20) Submitted: 4/2/2017 10:56:45 AM : Outperform Start Price: $32.45 FMI Score: +311.73

company involved in a promising new field of science - genomic diagnostics for dangerous diseases. The company has promising partnerships (eg with Roche) but it has yet to prove long term viability. Highly speculative


Find the members with the highest scoring picks in FMI.

Score Leader


majorguelth (57.82) Score: +708.79

The Score Leader is the player with the highest score across all their picks in FMI.

Member Name Member
Call Time
Score Commentary
majorguelth 57.82 1/14/2016 Outperform NS $16.19 +746.20% +37.41% +708.79 0 Comment
flounderuiuc 71.09 12/7/2015 Outperform 5Y $16.81 +714.99% +24.49% +690.50 0 Comment
coleman205 58.20 11/9/2015 Outperform 5Y $17.48 +683.75% +24.45% +659.30 0 Comment
SnoopyOne 82.36 3/14/2016 Outperform 5Y $18.24 +651.10% +28.48% +622.62 0 Comment
stereotyp72 59.74 1/24/2017 Outperform 5Y $18.60 +636.56% +15.05% +621.51 0 Comment
afurst < 20 10/9/2014 Outperform 1Y $19.18 +614.29% +32.67% +581.62 0 Comment
BRANTE 51.33 10/13/2014 Outperform 5Y $19.56 +600.41% +36.76% +563.65 0 Comment
misunderestimate < 20 5/19/2014 Outperform 5Y $20.37 +572.56% +38.78% +533.78 0 Comment
YMY 55.28 9/22/2014 Outperform 5Y $20.77 +559.61% +30.01% +529.60 0 Comment
truthwillsaveus < 20 5/15/2014 Outperform 5Y $21.00 +552.38% +38.06% +514.33 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for FMI.